GigaGen announced today that the United States Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application to initiate a Phase 1 trial to evaluate the company’s first recombinant polyclonal drug for the treatment of hepatitis B virus infection, GIGA-2339. GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus infection; trial initiation expected in Q4 2024
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols price target raised to EUR 15.45 from EUR 14.85 at Berenberg
- Grifols receives FDA approval for expanded XEMBIFY label
- Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Grifols board votes to grant Brookfield access to information